EFFICACY OF PAXLOVIDE IN THE TREATMENT OF COVID-19 PATIENTS WITH DIABETES TYPE 2

The Covid-19 pandemic is the most important global health problem of the 21st century. Diabetes Mellitus is considered one of the risk factors for worsening the course of covid-19 infection and the development of possible life-threatening complications. The aim of the study was to evaluate the effectiveness of Paxlovide in mild and moderate Covid-19 patients with diabetes, analysis of study results, and their consideration in clinical practice. The use of Paxlovide in treatment at the early stage of the disease – during the first 5 days is associated with rapid reduction: of the pathological symptoms, in the progression to a severe form, and in the risk of mortality in elderly patients. It’s important that observation of the patients took place during the dominance of the Omicron variant of the covid-infection in our country. Thus, it can be assumed that Paxlovid is effective against the omicron variant of covid-infection.